cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
Conventional Transarterial Chemoembolization (cTACE) or Transarterial Chemoembolization (DEB-TACE) +HAIC Combined With Regorafenib ± Anti-PD1 Antibody for Unresected Hepatocellular Carcinoma
Sponsor: Peking University Cancer Hospital & Institute
A observational or N/A phase clinical study on HCC and Hepatic Arterial Infusion Chemotherapy, this trial is ongoing. The trial is conducted by Peking University Cancer Hospital & Institute and has accumulated 6 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Sep 2023 — Jul 2024 [monthly]
Unknown Status
Status: Not Yet Recruiting → Unknown Status
-
Nov 2022 — Sep 2023 [monthly]
Not Yet Recruiting
-
Oct 2021 — Nov 2022 [monthly]
Not Yet Recruiting
▶ Show 1 earlier version
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Peking University Cancer Hospital & Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.